Background: Schizophrenia and treatment-resistant schizophrenia (TRS) are associated with aberrations in immune-inflammatory pathways. Increased High Mobility Group Protein 1 (HMGB1), an inflammatory mediator, and Dickkopf-Related Protein (DKK1), a Wnt/β-catenin signaling antagonist, affect the blood-brain-barrier and induce neurotoxic effects and neurocognitive deficits.
Introduction
The World Health Organization reported that schizophrenia (SCZ) patients die at a younger age as expected due to preventable physical diseases, such as cardiovascular disease, metabolic disease, and infections. 1 These diseases have an immune-inflammatory etiology and, therefore, those comorbidities may be explained by the neuro-immune theory of SCZ. The first comprehensive neuro-immune theory of SCZ was introduced by Smith and Maes in 1995 2 as the "macrophage-T-lymphocyte theory" considering that activated macrophages and T lymphocytes are key phenomena in the pathophysiology of SCZ. 2 Two years later, Maes and colleagues reported that SCZ is accompanied by an ongoing inflammatory response as indicated by increased plasma acute-phase proteins, such as fibrinogen, haptoglobin, hemopexin, α1-antitrypsin, and α1acid glycoprotein, as well as complement component 3 and complement 4 and immunoglobulins G and M. 3 In addition, these authors reported that increased plasma levels of interleukin (IL)-6, sIL-1 receptor antagonist (sIL-1RA), IL-8 and IL-10 are associated with treatment-resistant schizophrenia (TRS). [4] [5] [6] Those early findings on the immune-inflammatory response system (IRS) in SCZ are now well-replicated and synthesized in meta-analytic studies 7,8 while new studies also showed activated M1 macrophage (increased production of tumor necrosis factor-alpha (TNF-α) and IL-6); T helper (Th)-1 (increased levels of interferon (IFN)-γ and IL-2); Th-2 (IL-4 and IL-5), Th-17 (increased IL-17), and T regulatory (Treg) cell activation (increased IL-10), coupled with increased IgA levels to Gram-negative bacteria and neurotoxic tryptophan catabolites (TRYCATs) in SCZ. 9-14 Furthermore, new data show that TRS is characterized by activated M1 and Th-1 phenotypes, increased IL-6 trans-signaling (increased IL-6 and sIL-6R) and elevated chemokine levels including CCL2, CCL3, and CCL11. 13, 14 HMGB1 is increased in patients with SCZ or TRS and whether this protein is associated with increased IL-6 and IL-10 and impaired cognitive functions. Inflammation is also accompanied by an upregulation of Dickkopf-related protein 1 (DKK1), a pro-inflammatory glycoprotein secreted by platelets and endothelial cells. 24 
DKK1
antagonizes the canonical Wnt signaling transduction pathway and therefore may interfere with tissue regeneration and repair and, additionally, may induce a rapid disassembly of synapses in mature neurons. 24, 25 This is further underscored by recent findings that circulating DKK1 is associated with cognitive decline in older adults. 26 Moreover, in a Japanese population, DKK1 genetic variants are associated with SCZ. 27 However, there are no data whether increased DKK1 levels are associated with SCZ, TRS, and neurocognitive impairments and symptom severity.
Hence, the aims of the study are to 1) examine whether HMGB1 and DDK1 are increased in SCZ and TRS, and 2) delineate the association between both proteins and established markers of SCZ (IL-6, IL-10, and CCL11), SCZ symptom subdomains and neurocognitive impairments.
Participants and Methods

Participants
Sixty TRS patients and fifty-five non-TRS patients, as well as 43 healthy controls (both sexes, ages between 18 and 65 years), were recruited to participate in the current study. All patients were recruited at the Psychiatry Unit at Al-Imam Al-Hussain Medical City in Karbala Governorate-Iraq in 2019. All patients complied with the diagnostic criteria of SCZ according to the DSM-IV-TR .
TRS is defined as two periods of treatment nonresponse to two different antipsychotic treatments at adequate doses, each for at least 8 weeks, without a reduction in symptoms as screened with the
Measurements
Clinical assessments
The diagnosis of SCZ was made by a senior psychiatrist specialized in SCZ according to DSM-IV-TR diagnostic criteria using the Mini-International Neuropsychiatric Interview (M.I.N.I.), in a validated Arabic translation (Iraqi dialect). The same day as the M.I.N.I., the same psychiatrist employed a semi-structured interview to assess demographics as well as clinical data in all participants and he also measured the CGI-I and Severity (CGI-S) scale. 28 The CGI-I was used to define patients who were non responders to treatment (NRTT), namely those who did not show any change in the CGI-I or showed worse scores after treatment (minimally worse, much worse, very much worse) and those who were partial RTT (PRTT), namely those with improved scores (minimally, much or very much). Not one of the patients showed complete remission after treatment. He also assessed the Scale for the Assessments of Negative Symptoms (SANS) to assess the severity of negative symptoms. 29 We computed scores reflecting PHEM (psychosis, hostility, excitation, and mannerism) symptoms, FTD (formal thought disorders) and PMR (psycho-motor retardation) as explained previously. 16, 19 Towards this end we also assessed the Brief Psychiatric Rating Scale (BPRS), 30 the Hamilton Depression Rating Scale 31 and the positive and negative syndrome scale (PANSS) for schizophrenia. 32 On the same day, a well-trained research psychologist, blinded to the clinical diagnosis, completed the Brief Assessment of Cognition in SCZ (BACS) 33 to assess episodic memory using the List Learning test; working memory with the Digit Sequencing Task; verbal fluency and semantic memory employing Category Instances and Controlled Word Association tests; attention using the Symbol Coding test, and executive functions using the Tower of London. DSM-IV-TR criteria were used to make the diagnosis of Tobacco Use Disorder (TUD). Body mass index (BMI) was measured on the same day as the clinical interview and was scored as body weight (kg) / length (m 2 ).
Assays
After an overnight fast, five milliliters of venous blood were sampled, utilizing disposable needle and plastic syringes, between 8.00 and 9.00 a.m. The samples were transferred into a clean plain tube; blood was left at room temperature for 15 min for clotting, centrifuged 3000 rpm for 10 min, and then serum was separated and transported into two Eppendorf tubes to be stored at -80 °C until thawed and analyzed. Commercial ELISA sandwich kits were used to measure serum CCL11, DKK1, HMGB1, and IL-10 (Elabscience ® , Inc. CA, USA) and IL-6 (Melsin Medical Co, Jilin, China). All measured concentrations of CCL11 (sensitivity=9.38 pg/mL), DKK1 (sensitivity=18.75 pg/mL), HMGB1 (sensitivity=18.75 pg/mL), and IL-6 (sensitivity=0.1 pg/mL) were greater than the sensitivity of the assays. There was only one IL-10 concentration (4.05 pg/mL in a normal volunteer) that was lower than the sensitivity of the assay (sensitivity=4.69 pg/mL). We did not apply left-censoring and used the actual measurements in the statistical analyses. 12 The procedures were followed exactly without modifications according to the manufacturer's instructions. The intra-assay coefficient of variation (CV) (precision within an assay) were < 10.0%. Serum CRP was measured using a kit supplied by Spinreact ® , Spain. The test is based on the principle of latex agglutination.
Statistical analysis
Analysis of variance (ANOVA) was used to check differences in scale variables between categories and analysis of contingency tables (χ2-test) was to assess associations between nominal variables. In order to assess associations among the biomarkers, clinical and cognitive scores we examined correlation matrices based on Pearson's product-moment and Spearman's rank-order correlation coefficients. We used multivariate general linear model (GLM) analysis to delineate the associations between diagnosis and the biomarkers while controlling for confounding variables including nicotine dependence, sex, age, BMI and education. Consequently, we carried out tests for between-subject effects to delineate the associations between diagnosis and each of the biomarkers. The effect size was estimated using partial eta-squared values. We also computed model generated (GLM analysis) estimated marginal mean (SE) values and protected pairwise comparisons among treatment means. We employed binary logistic regression analysis to delineate the best predictors of NRTT (PRTT as reference group) and SCZ (controls as reference group) using the biomarkers as explanatory variables. Odd's ratios with 95% confidence intervals were computed as well as Nagelkerke values as pseudo-R 2 values. We used multiple regression analysis to assess the significant biomarkers, which predict the symptom domains and neurocognitive tests while allowing for possible effects of age, sex, and education. We used an automatic stepwise method with the inclusion of variables with a p-to-entry of 0.05 and p-to-remove of 0.06 while checking the R 2 change. All regression analyses were checked for collinearity using tolerance and VIF values. Variables were also z transformed and the mean z scores were displayed in bar plots.
Tests were 2-tailed and a p-value of 0.05 was used for statistical significance. All statistical analyses were performed using IBM SPSS windows version 25, 2017. Table 1 shows the sociodemographic data of the NRTT, PRTT and healthy controls. In this study, we recruited 142 SCZ patients who were treated with antipsychotic drugs during two trials with antipsychotic drugs. During the first trial, patients were treated for 8 weeks and after this trial divided into those without a clinical response (n=84) and a partial response (n=51) (we lost 7 patients during this first trial). The partial responders continued to take the same medication for another 2 months while we lost again 7 patients in the follow up yielding a final PRTT study group of n=55. The non-responders to a first antipsychotic agent were switched to another antipsychotic agent for another 8 weeks and during this follow-up period we lost again 13 patients.
Results.
Socio-demographic data
Two months later, 11 patients showed a partial response to treatment and were classified as PRTT, whereas 60 did not show any improvement on the CGI-I and, therefore, were classified as NRTT.
Consequently, 55 PRTT and 60 NRTT were recruited to participate in the study.
There were no significant differences in age, sex ratio, BMI, and TUD between PRTT and NRTT and normal controls. There were somewhat more NRTT who were single than normal controls. Significantly more SCZ patients were unemployed as compared with controls while years of education were somewhat lower in NRTT. There were no differences in age at onset between both SCZ subgroups. All 6 cognitive test scores were significantly different between the three study groups and the scores decreased from controls to PRTT to NRTT. The total SANS score was significantly different between the three study groups. Figure 1 displays a plot of all symptom domains examined in this study (shown as z scores). Psychosis (F=772.55, df=2/152, p<0.001), hostility (F=498.12, df=2/152, p<0.001), excitement (F=320.71, df=2/152, p<0.001), mannerism (F=204.41, df=2/152, p<0.001), FTD (F=414.15, df=2/152, p<0.001) and PMR (F=297.46, df=2/152, p<0.001) were significantly different between the three study groups and increased from controls to PRTT to NRTT. Table 1 shows also the measurement of the clinical global impression (CGI) score in the SCZ patients. Both the CGI-I and CGI-S scores were significantly higher in NRTT than in PRTT. All CGI-I scores in PRTT equaled 2 (much improved) or 3 (minimally improved) and in NRTT 4 (no change) or 5 (minimally worse). The table also shows the current medication patients were taking. Thus, NRTT were more often treated with clozapine, quetiapine, and risperidone than PRTT who were more often treated with olanzapine and haloperidol.
Biomarkers between the study groups
In the total study group, there were significant correlations between IL-6 and DKK1 (r=0.641, p<0.001, n=158) and HMGB1 (r=0.249, p=0.002, n=158) and a significant association between IL-10 and HMGB1 (r=0.465, p<0.001, n=158). The correlation between IL-6 and HMGB1 was established in controls (r=0.649, p<0.001, n=43) and SCZ patients (r=0.561, p<0.001, n=115). A significant correlation between IL-10 and DKK1 was detected in controls (r=0.395, p=0.009, n=43) and SCZ patients (r=0.430, p<0.001, n=115). Table 2 shows the results of multivariate GLM analyses comparing the differences in the biomarkers between the three study groups while adjusting for sex, age, BMI and TUD. There were highly significant differences in the biomarkers between the groups with an effect size of 0.245, while the 4 covariates had no significant effects. Tests for between-subject effects and Table 3 , which shows the estimated marginal means, indicate that DKK1 and IL-6 were significantly higher is NRTT than in PRTT and controls and that HMGB1 was significantly different between SCZ and controls. IL-10 was higher in NRTT than in controls while PRTT patients occupied an intermediate position. Table 4 shows the results of two binary logistic regression analyses examining the best predictors of SCZ (versus controls) and NRTT (versus PRTT) using an automatic stepwise method with biomarkers as explanatory variables while allowing for the effects of age, sex and education.
The first regression analysis showed that SCZ was best predicted by increased levels of DDK1 and HMGB1 (χ2=60.58, df=2, p<0.001, Nagelkerke=0.462) while the accuracy was 74.7% with a sensitivity of 72.2% and a specificity of 81.4%. The second regression shows that IL-6 combined with CCL11 were the best predictors of NRTT versus PRTT (χ2=25.84, df=2, p<0.001, Nagelkerke=0.268).
Effects of background variables.
As described above there were no significant effects of age, sex, BMI and TUD on the biomarkers included. In patients with SCZ, we also examined the effects of the use of antipsychotics on the biomarkers. Multivariate GLM analysis followed by tests for betweensubjects effects showed that there were no significant effects of use of haloperidol (F=0. after p-correction for multiple testing this effect was no longer significant (p=0.195). Tests for between-subjects effects showed a significant effect on CCL11 only (F=7.67, df=1/108, p=0.007, partial eta squared=0.066). This effect remained significant after p-correction for false discovery rate (p=0.04). The use of olanzapine significantly increased CCL11 levels (176.3 ±14.4 versus 220.1 ±9.1 pg/ml). However, the differences between the diagnostic groups in CCL11 were not affected after covarying for use of olanzapine. Table 5 shows different stepwise multiple regression analyses with the symptom domains as dependent variables and the 5 biomarkers as explanatory variables while allowing for the effects of age, sex, and education. Regression #1 shows that 35.6% of the variance in the total SANS score was explained by the regression on HMGB1, IL-6, and CCL11. Regressions #2, #3 and #4 show that the same variables explained a considerable part of the variance in psychosis (32.2%), hostility (30.7%), and excitation (29.9%). Regression #5 shows that 32.0% of the variance in mannerism was explained by HMGB1, DKK1, and CCL11. Figure 2 shows the partial regression plot of the mannerism scores on HMGB1 levels. IL-6 and HMGB1 together explained 22.2% of the variance in PMR (regression #6). Regression #7 shows that 36.9% of the variance in FTD was explained by the combined effects of HMGB1, IL-6, CCL11, and education. In all regressions, HMGB1 was the variable with the highest impact (except for PMR). Table 6 shows the outcome of 6 multiple regression analyses with the cognitive test results as dependent variables and biomarkers as explanatory variables while allowing for the effects of age, sex and education. We found that (regression #1) 20.6% of the variance in List Learning scores was explained by the regression on HMGB1, DKK1 and CCL11 (all inversely associated) and education (positively associated). Up to 33.5% of the variance in Digit Sequencing Task scores (regression #2) was explained by the combined effects of HMGB1, IL-6, CCL11 (inversely) and education (positively). Part of the variance (20.7%) in Category Instances scores was explained by HMGB1, DKK1 (negatively) and education (positively). We found that 33.4% of the variance in the COWA test (regression #4) scores was explained by the cumulative effects of HMGB1 and IL-6 (both negatively) while 39.5% of the variance in Symbol Coding scores (#5) was associated with HMGB1 and DKK1. Figure 3 shows the partial regression plot association between Symbol Coding scores and HMGB1 levels. Regression #6 shows that part of the variance in the Tower of London scores was explained by HMGB1 and DKK1 (inversely) and education (positively).
Prediction of symptom domains by biomarkers
Prediction of cognitive impairments by biomarkers
Discussion
The first major finding of this study is that SCZ is characterized by increased levels of HMGB1, DKK1, IL-6, and CCL11 as compared with healthy controls. Our results that IL-6 and CCL11 are increased in SCZ are in accordance with findings in previous studies. 5,12,13, 17-19, 34,35 This is the first study that HMGB1 is significantly increased in SCZ versus normal volunteers. HMGB1 is a transcriptional modifier that acts as a pro-inflammatory cytokine promoting the release of other cytokines, including IL-6. 21 HMGB1 is normally localized in the nucleus but following immune-inflammatory signals, including LPS and TNF-α, HMGB1 is translocated to the cytoplasm and may aggregate and accumulate in secretory lysosomes to be secreted from activated monocytes, macrophages and natural killer cells. [36] [37] [38] Moreover, extracellular HMGB1 engages membrane receptors leading to immune activation and neuroinflammation. 39 HMGB1 is a DAMP that may activate the TLR2 and TLR4 complex thereby contributing to danger signaling leading to immune-inflammatory signals. 20 Moreover, hemoglobin released from lysed red blood cells may synergize with HMGB1 to stimulate the production and release of pro-inflammatory cytokines. 40 On the other hand, haptoglobin may form a complex with HMGB1 thereby stimulating an immune-regulatory response with increased levels of IL-10. 40 In this respect, we found that HMGB1 levels are significantly and positively associated with IL-6 and IL-10, indicating that increased HMGB1 is part in the immune-inflammatory pathophysiology of SCZ. This is also the first report that serum DKK1 concentrations are significantly increased in SCZ. DKK1 is secreted by endothelial cells and platelets while the latter are essential to raising plasma DKK1 levels. 24, 41 In humans, a dramatic increase in systemic DKK1 is observed in acute infections 42 while platelet-derived DKK-1 contributes to elevated systemic levels in infectious models. 41 In mice, LPS may increase the expression of DKK1 and IL-6 43 while in the present study, there were significant and positive correlations between IL-6 and DKK1. Nevertheless, there is a study reporting lowered DKK1 levels in SCZ patients while these authors found upregulated mRNA expression of Wnt signaling pathway genes. 44 It is important to note that both DKK1 and IL-6 and other cytokines, which are increased in SCZ (including TNF-α), may inhibit activation of the Wnt-β-catenin signaling pathway. 44 The second major finding of our study is that NRTT was associated with increased DKK1, IL-6, and CCL11 concentrations as compared with NTRR and that IL-10 is, additionally, significantly increased in NRTT as compared with controls. These findings indicate that a partial treatment response is characterized by attenuated immune-inflammatory pathways (IL-6 and CCL11) and maybe by inhibition of the Wnt pathway (as a consequence of increased DKK1).
While our DKK1 results are novel, increased IL-6 and IL-10 levels were previously reported in patients with TRS. 4, 6 Our results further extend the findings that TRS is accompanied by IRS activation as indicated by increased levels of sIL-6R, IL-8, CCL2 and CCL3, and by CIRS activation as indicated by elevated levels of sIL-1RA, sTNFR1, and sTNFR2. 4-6, 13,14 Noto et al. 45 reported that drug naïve first-episode psychosis is characterized by significant IRS (M1 + Th-1 + Th-17) and CIRS (Th-2 and Treg) responses and that treatment with risperidone attenuates both IRS and CIRS responses while increased baseline levels of some CIRS biomarkers may predict clinical improvement. All in all, the above results and the current study indicate that antipsychotic agents may attenuate the immune response in some SCZ patients, namely in PRTT, thereby improving symptoms and neurocognitive deficits.
The third major finding of this study is that the different symptom domains of SCZ (including PHEM and negative symptoms and FTD) are highly significantly predicted by increased HMGB1, IL-6 and CCL11, while impairments in executive functions, working memory and episodic and semantic memory, and attention are predicted by increased levels of especially HMGB1 and DKK1 but also CCL11. Previously, we reported that CCL11 and IL-6 and other neurotoxic immune compounds (see Introduction) significantly predict PHEM and negative symptoms, FTD and PMR suggesting that immune-inflammatory pathways are involved in the pathophysiology of SCZ. 12, 18, 19 There is now evidence that HMGB1 plays an important role not only in the propagation of immune-inflammatory responses (see above), but also in neuroinflammatory and neurodegenerative processes and the associated memory impairments in Parkinson's and Alzheimer's disease and multiple sclerosis. 46 HMGB1 released from necrotic neurons or inflamed microglia may act on microglia macrophage antigen complex 1 thereby stimulating the production of multiple neurotoxic factors. 47 HMGB1 may cause neurite degeneration via the TLR4 complex and phosphorylation of MARCKS via MAP kinases. 48 On the other hand, HMGB1-specific antibodies protect against lethal endotoxaemia 20 and preserve BBB integrity thereby attenuating glial activation, oxidative stress and elevated inflammatory gene expression, including IL-6, damage to hippocampal neurons, neuronal degeneration, and brain damage. 49, 50 Furthermore, blocking of HMGB1 signaling improves neuroprotection in neurodegenerative disorders. 51 Clinical studies show that sepsis survivors have permanent cognitive deficits, which are probably mediated via elevated HMGB1 levels. 52 As described above, DKK1 is a natural antagonist of the Wnt/β-catenin signaling pathway, 53 which is a key regulator of BBB function and contributes to its formation, maturation, and function. [54] [55] [56] Elevating β-catenin signaling leads to lowered permeability of the endothelial cells of the BBB, 56 whereas DKK1-induced aberrations in Wnt/β-catenin signaling may induce BBB breakdown. 57, 58 Moreover, administration of DKK1 to a mixture of human neurons and astrocytes in culture results in downregulation of neuronal processes explaining that lowering DKK1 protects against neurotoxicity. 59 DKK1 mediates amyloid-ß-associated synaptic loss, causes a rapid disassembly of synapses in mature neurons, 25 induces BAX and decreases Bcl-2 thereby causing cell death. 60 Moreover, loss of DKK1 may counteract the downregulation of hippocampal neurogenesis and accompanying cognitive impairments that are associated with increasing DKK1 levels with age. 61 This may explain that DKK1 deficient mice show improved working memory, memory consolidation and affective behaviors. 61 It is important to note that the effects of HMGB1 and DKK1 affecting BBB functions may aggravate the effects of CCL11, neurotoxic TRYCATs and LPS which all lead to breakdown of the BBB in SCZ. 11
Limitation of the study
The results of our study should be discussed with respect to its limitations. First, we performed a case-control study and, therefore, no firm causal inferences may be established.
Second, it would have been more interesting if we had examined haptoglobin and hemoglobin in relation to HMGB1 as well as a broader panel of cytokines. Finally, we found that treatment with olanzapine significantly increased CCL11 levels from 176.3 ±14.4 to 220.1 ±9.1 pg/ml, which if replicated in ex vivo and in vivo studies, would suggest that olanzapine may augment the detrimental effects of CCL11. Nevertheless, our intergroup analyses were adjusted for the drug state, which did not affect the differences in CCL11 between the study groups.
Conclusions
HMGB1, DKK1, IL-6, and CCL11 were significantly higher in SCZ patients, whereas a non-response to treatment with antipsychotics was associated with increased DKK1, IL-6 and CCL11. Both HMGB1 and DKK1 were significantly correlated with IL-6 levels. HMGB1 and DKK1 participate in the immune pathophysiology of SCZ and may explain, in part, the phenome of SCZ (neurocognitive impairments and various symptom clusters) via their detrimental effects on the BBB and multiple neurotoxic effects as well. OR: Odds ratio, 95% CI: 95% confidence intervals CCL11: CC-motif chemokine 11 or eotaxin; DKK1: dickkopf protein 1; HMGB1: high mobility group box 1 protein; IL: interleukin. 
